Insider buying last 90 days
No open-market insider purchases were filed for WST in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every WST insider filing, plotted on the chart in Gekko.Open WST in Gekko
NYSE: WST
West Pharmaceutical Services (WST) Stock Analysis & Forecast
Sep 28 close
$375.65+5.21 (+1.4%)
Gekko Brief
AI summaryWest Pharmaceutical Services has drawn attention this week on continued momentum in its biologics and GLP-1 program exposure, alongside management commentary on recovery from a cyberattack and changes in the West Vantage business. Morgan Stanley upgraded the stock to Overweight and raised its price target from USD 365 to USD 400, citing Q2 2026 revenue of USD 872.3 million that exceeded analyst estimates along with an earnings per share beat. Other coverage has focused on comparisons with competitors including Chemed, Encompass Health, Medline, Alcon and Solventum, and on the stock trading at 46.1x earnings versus a cited fair ratio of 23.6x.
WST closed at $375.65, up 1.4%, sitting above both its 50-day average of $350.79 and its 200-day average of $300.33, with the 50-day above the 200-day. The GekkoIndex reads 45.7, placing the stock in the Neutral zone, down 2.9 over five sessions. The price sits 17% above Gekko Fair Value of $321.01.
Earnings are scheduled for 22 October, 23 days out and within a typical 20-day hold, with the prior report on 23 July showing an EPS beat and a -8.4% reaction. Consensus among 10 firms is unanimously Buy with a $407.56 target, an 8.5% upside. No insider, Congress or unusual options activity appears in the recent windows. Historically, the next 20 trading days from this point averaged -3.9% over 5 years, rising in 1 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
West Pharmaceutical Services price vs fair value
Close $375.65200-day averageGekko Fair Value $321.01
West Pharmaceutical Services quick facts
- Market cap
- $26.43B
- P/E ratio
- 47.8
- Forward P/E
- 37
- EPS, TTM
- $7.82
- Revenue, TTM
- $3.33B
- Profit margin
- 17%
- Dividend yield
- 0.23%
- Beta
- 1.14
- Volume
- 567,551 avg 606,170
- 1-year return
- +47.6%
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±5.4%
- 50-day average
- $350.79
- 200-day average
- $300.33
- Next earnings
- Oct 22 before open
- Shares outstanding
- 70.38M
West Pharmaceutical Services swing-trade checklist
West Pharmaceutical Services scores 1 supportive, 1 mixed and 3 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
1 supportive1 mixed3 headwinds
- Trendsupportive
Above 50 and 200-day
Close $375.65 is above the 50-day ($350.79) and 200-day ($300.33) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
45.7, Neutral
Reading 45.7 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
17.0% above
Price is 17% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 23 days
Reports on Oct 22, 2026, 23 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−3.9% on average
From this point in the calendar, the next 20 trading days averaged −3.9% over 5 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
West Pharmaceutical Services stock chart and price history
West Pharmaceutical Services closed at $375.65 on Sep 28, 2026, +47.6% over the past year, inside a 52-week range of $223.83 to $386.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +8.5%
- 3 months
- +5.9%
- 6 months
- +54.4%
- 1 year
- +47.6%
The full WST chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open WST in Gekko
Follow West Pharmaceutical Services through every session
Put WST on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track WST in GekkoFree for 7 days. No credit card required.
About West Pharmaceutical Services
West Pharmaceutical Services designs, manufactures, and distributes components used to package and deliver injectable medicines and other healthcare products. It is best known for parts such as stoppers, seals, and syringe and cartridge components that protect and administer injectable drugs, along with devices that support mixing, reconstitution, and self-injection.
The company organizes its work into two units. Its Proprietary Products business supplies packaging components, drug containment materials, self-injection devices, and support services such as lab analysis, packaging assistance, engineering, regulatory help, and technical support, mainly for makers of biologic, generic, and other pharmaceutical products. Its Contract-Manufactured Products business designs and assembles devices for surgical, diagnostic, ophthalmic, and drug delivery use, as well as consumer items, serving pharmaceutical, diagnostic, and medical device manufacturers. Products reach buyers worldwide through its own sales force, distribution network, and outside sales agents and distributors, with operations across the Americas, Europe, the Middle East, Africa, and Asia Pacific.
West Pharmaceutical Services was founded in 1923 and is headquartered in Exton, Pennsylvania. Its shares are listed on the NYSE under the ticker WST.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Medical specialties
- Website
- westpharma.com
West Pharmaceutical Services GekkoIndex: the smart money zone
West Pharmaceutical Services’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.7, in the Neutral zone, down 2.9 points over five sessions.
45.7Neutral
Down 2.9 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 35 | +2.4% | +4.4% | ||
| Accumulation | 205 | −0.1% | −0.4% | ||
| Neutral (current zone) | 394 | +0.4% | +0.7% | ||
| Distribution | 35 | −1.8% | −3.3% | ||
| Selling | 3 | Too few readings yet | |||
Average WST share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the WST price, zone by zone.Track WST in Gekko
Is West Pharmaceutical Services stock overvalued? Gekko Fair Value
West Pharmaceutical Services trades 17.0% above Gekko Fair Value of $321.01, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what West Pharmaceutical Services shares are worth, recalculated every trading day.
$321.01
Gekko Fair Value, Sep 26, 2026
17.0% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open WST in Gekko
West Pharmaceutical Services insider and Congress trading
No open-market insider purchases were filed for West Pharmaceutical Services, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in WST were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for WST, plotted on the chart in Gekko.Open WST in Gekko
Buybacks
West Pharmaceutical Services has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $297.6M
- As a share of market cap
- 1.13%
- Trailing four quarters
- $595.5M
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold WST.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
West Pharmaceutical Services earnings: next date and track record
West Pharmaceutical Services reports on Oct 22, 2026, before the open (23 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Oct 22, 2026
Expected before the open, 23 days away
- EPS estimate
- $2.19
- Revenue estimate
- $826.0M
8 of 8reports beat the EPS estimate
±11%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 23, 2026 AI summary
- What they said
- West Pharmaceutical Services reported a strong Q2 2026: revenues of $872 million, organic revenue growth of ~13% and adjusted EPS of $2.37 (up 29% y/y). Management cited execution against strategy and operational improvements (notably recovery actions following a cyber incident) as key drivers. Proprietary Products (particularly HVP Components and Biologics) were the primary growth engines; HVP Components represented ~49% of revenues and grew strongly both in GLP-1 and non-GLP-1 areas. Management raised full-year guidance for organic revenue growth to 10%–11% and adjusted EPS to $8.85–$9.05. Key strategic drivers discussed were Biologics/biosimilars, GLP-1s, Annex 1-driven HVP upgrades, and continued expansion in Delivery Devices (including SmartDose 3.5 and SelfDose). Management expressed confidence in multi-year opportunities (Annex 1, geographic expansion in APAC, GLP-1 biosimilars), while noting some near-term conservatism in the back half due to timing/ramps (West Vantage, Dublin) and the need to take a prudent quarter-by-quarter approach.
- Guidance
- Raised full year 2026 guidance: organic revenue growth to 10%–11%; adjusted EPS range $8.85 to $9.05. Additional commentary: GLP-1 HVP Components expected to continue double-digit growth and high-teens for GLP-1s for the full year; Proprietary Products mid/low double-digit (non-GLP HVP high teens). West Vantage drug handling revenue expected ~$20 million in 2026 (back-half loaded).
- Risks flagged
- Cyber incident impacts and recovery/timing risk; capacity and ramp risks (Dublin ramping, West Vantage throughput timing); near-term conservatism in guidance which may reflect execution/timing uncertainty; SmartDose integration/divestiture and its previous dilutive margin impact; commodity and energy cost volatility (and related price pass-through uncertainty); regulatory and market adoption timing (e.g., Annex 1 spillover, Medicare/market ramps for GLP-1s).
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 23, 2026 | $2.37 est $2.08 | $872.3M est $840.0M | −8.4% |
| Apr 23, 2026 | $2.13 est $1.68 | $844.9M est $780.3M | +11.6% |
| Feb 12, 2026 | $2.04 est $1.83 | $805.0M est $794.9M | +1.8% |
| Oct 23, 2025 | $1.96 est $1.68 | $804.3M est $785.7M | +7.4% |
| Jul 24, 2025 | $1.84 est $1.54 | $766.2M est $726.1M | +15.9% |
| Apr 24, 2025 | $1.45 est $1.26 | $698.0M est $713.0M | −1.7% |
| Feb 13, 2025 | $1.82 est $1.71 | $748.8M est $740.5M | −33.4% |
| Oct 24, 2024 | $1.85 est $1.50 | $746.9M est $709.6M | +7.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
West Pharmaceutical Services stock forecast and analyst price targets
Analysts’ average 12-month price target for West Pharmaceutical Services is $407.56, +8.5% from the last close, from 10 firms rating the stock in the last 90 days.
$407.56consensus 12-month target, +8.5% from the last close
Now $375.65Avg $407.56
Low $390High $447
Each firm’s latest rating in the last 90 days: 10 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 22 | Morgan Stanley | $400 | +6.5% |
| Sep 14 | Morgan Stanley | $365 | −2.8% |
| Sep 9 | UBS | $415 | +10.5% |
| Aug 3 | Citi | $412 | +9.7% |
| Jul 27 | Evercore ISI | $425 | +13.1% |
+0.7%average 20-day move after past Neutral readings
−3.9%average move over the next 20 trading days in the last 5 years
±2.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
West Pharmaceutical Services seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, West Pharmaceutical Services averaged −3.9% across the last 5 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −0.7% | 3 of 5 |
| Next 10 trading days | −1.9% | 2 of 5 |
| Next 15 trading days | −3.0% | 1 of 5 |
| Next 20 trading days | −3.9% | 1 of 5 |
| Next 30 trading days | −1.5% | 2 of 5 |
For scale, WST’s typical 20-trading-day move in either direction is about 5.4%.
West Pharmaceutical Services market cap and key statistics
West Pharmaceutical Services’s market cap is $26.43B, with a P/E ratio of 47.8 and revenue of $3.33B over the last twelve months.
Valuation
- Market cap
- $26.43B
- P/E ratio
- 47.8
- Forward P/E
- 37
- EPS, TTM
- $7.82
- Gekko Fair Value
- $321.01
Trading
- Volume
- 567,551
- Avg volume, 20 days
- 606,170
- 52-week high
- $386.00
- 52-week low
- $223.83
- Shares outstanding
- 70.38M
Financials
- Revenue, TTM
- $3.33B
- Profit margin
- 17%
- Return on equity
- 19.1%
- Quarterly earnings growth, YoY
- +18.1%
Risk and income
- Beta
- 1.14
- Typical daily move
- ±2.5%
- Typical 20-day move
- ±5.4%
- Dividend yield
- 0.23%
West Pharmaceutical Services stock news this week
Coverage of West Pharmaceutical Services this week reads positive: 7 positive, 1 neutral and 1 negative headlines.
- West Pharmaceutical Services stock last traded at USD 374.83 on September 28, 2026AD HOC NEWS, Sep 28
- West Pharmaceutical Services, Inc. (WST) Latest Stock News & Headlines - Yahoo FinanceYahoo! Finance Canada, Sep 28
- West Pharmaceutical Services (WST) Is Back In The Spotlight, What Is Catching Attention?Simply Wall Street, Sep 28
- West Pharmaceutical Services, Inc. (WST) Stock Price, News, Quote & HistoryYahoo! Finance Canada, Sep 26
- Top West Pharmaceutical Services (WST) Competitors 2026MarketBeat, Sep 25
- West Pharmaceutical Services stock gains after target risesAD HOC NEWS, Sep 24
West Pharmaceutical Services peers
West Pharmaceutical Services’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Distribution | 23.7% above |
| ABTAbbott Laboratories | Accumulation | 15.0% below |
| DHRDanaher | Distribution | 10.2% above |
| ISRGIntuitive Surgical | Neutral | 17.0% above |
| MDTMedtronic | Accumulation | 24.1% below |
| SYKStryker | Accumulation | 14.1% below |
A peer links to its own page where one exists.
West Pharmaceutical Services stock FAQ
What is West Pharmaceutical Services’s market cap?
West Pharmaceutical Services’s market cap is $26.43B at the Sep 28, 2026 close of $375.65, with 70.38M shares outstanding. The shares trade on a P/E ratio of 47.8.
What is the West Pharmaceutical Services stock forecast?
The consensus analyst 12-month price target for West Pharmaceutical Services is $407.56, +8.5% from the last close. Of the 10 firms that rated the stock in the last 90 days, 10 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is West Pharmaceutical Services stock overvalued or undervalued?
On Gekko’s estimate West Pharmaceutical Services is overvalued: the Sep 28, 2026 close of $375.65 is 17.0% above Gekko Fair Value of $321.01. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does West Pharmaceutical Services report earnings next?
West Pharmaceutical Services is expected to report on Oct 22, 2026, before the market opens (23 days away). Analysts expect earnings of $2.19 per share on revenue of $826.0M. West Pharmaceutical Services beat the earnings estimate in 8 of its last 8 reports, moving 11% on average across the report.
What is West Pharmaceutical Services’s 52-week high and low?
West Pharmaceutical Services’s 52-week high is $386.00 and its 52-week low is $223.83; it closed at $375.65 on Sep 28, 2026, +47.6% over the past year. Over the last five years the shares peaked at $475.00 on Dec 27, 2021.
Is West Pharmaceutical Services stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 1 of the 5 items with data read as supportive (trend), 1 as mixed (gekkoindex) and 3 as headwinds (fair value, earnings risk and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See West Pharmaceutical Services the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.